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Summary 
We used severe combined immunodeficient (SCID) mice to study resistance to invasive infection 
with Entamoeba histolytica.  Seven of seven SCID mice developed liver abscesses when challenged 
intrahepatically with virulent HMI:IMSS strain 15. histolytica  trophozoites. Only one of seven 
similarly challenged immunocompetent congenic C.B-17 mice developed  an abscess. Adoptive 
transfer of polyclonal rabbit  anti-E,  histolytica  antiserum, but  not preimmune rabbit  serum, 
completely protected 7 of 12 SCID mice from intrahepatic challenge with ameba. These results 
demonstrate that lymphocyte-based immunity is important in protection against amebic liver 
abscess, and that anti-E, histolytica  antibody can protect against amebic infection in this system. 
The SCID mouse may provide a powerful model for studying the components of protective 
immunity to invasive amebiasis. 
T 
he protozoan Entamoeba  histolytica  causes an estimated 
36,000,000 cases of disabling colitis or liver abscess and 
kills at least 40,000 people annually, ranking it third world- 
wide among parasitic causes of death (1). Despite intensive 
research over the past two decades, the precise mechanisms 
of protective immunity to amebiasis have not been defined 
(2). Part of the problem has been the lack of a suitable animal 
model. 
SCID mice lack functional B and T cells (3), a defect that 
can be corrected adoptive transfer of normal routine spleno- 
cytes (4). SCID mice have intact macrophage and NK cell- 
mediated immunity (5, 6). SCID mouse models have proved 
useful in studies of resistance to a number of viral (7-9), bac- 
terial (10, 11), helminth (12), and protozoan pathogens (13, 
14). We report here the establishment of a SCID mouse model 
for amebic liver abscess, and the use of this model to demon- 
strate that immune serum protects against visceral E. histolytica 
infection. 
Materials  and Methods 
Cells.  E. histolytica, strain HMI:IMSS (15), passaged three times 
through hamster liver, was kindly provided by Dr. V. Tsutsumi 
(Center for Research and Advanced  Studies, National Polytechnical 
Institute, Mexico City, Mexico). The strain was maintained in our 
laboratory by subculturing twice weekly in axenic  BI-S-33 medium 
(16) and passaged  bimonthly through hamster liver to ensure con- 
tinued virulence (17). 
Animals.  C.B-17-SCID mice and immunocompetent congenic 
C.B-17 mice were bred in a barrier facility at Washington Univer- 
sity  School of Medicine. Lack of infection with adventitious 
pathogens was documented using sentinel mice, intermittent sero- 
logic assessment of retired breeder C.B-17 mice, and inoculation 
of tissues from retired breeder SCID mice into C.B-17 recipients 
followed by serologic testing for murine viral pathogens. 
Hepatic  Inoculation.  Log-phase (72-h) cultures E.  histolytica 
HMI:IMSS trophozoites  were chilled  on ice for 5 min. Trophozoites 
were pdleted by centrifuging at 500 g for 5 rain, counted on a 
hemocytometer,  and resuspended  in 100/~1 BI-S-33 medium to yield 
a final concentration of *2,5  x  106 amebas/100/A. Tubes con- 
taining amebas were kept on ice pending inoculation, which oc- 
curred within 5-10 min after resuspension. 
SCID mice  and C.B-17 controls, weighing 20--25 g, were anesthe- 
tized intraperitoneally with 58 mg/kg ketamine and 8.7 mg/kg 
xylazine. After povidone-iodine  scrub, a vertical  incision, 1-1.5 cm 
in length, was made in the anterior abdominal wall. The perito- 
neal cavity was subsequently entered, and the 100/~1 amebic in- 
oculum (2.5  x  106 trophozoites) was administered by direct in- 
trahepatic injection from a 1-ml tuberculin syringe via 26-gauge 
needle so that a visible  bleb was raised. The peritoneum was closed 
with 4-0 chromic gut sutures and the abdominal wall with 7-mm 
Michel clips. The animals were returned to their cages and killed 
7 d later. The entire liver was removed, weighed, and any abscess 
detected was resected and weighed. The percentage  of  liver abscessed 
was calculated  as the weight of  the abscess divided  by the liver  weight 
before abscess removal. Specimens  for histology obtained from each 
abscessed and visually  normal liver  were fixed  in formalin, sectioned, 
and stained with hematoxylin and eosin. 
Ikcsive Immunization.  Immune serum was obtained  from a rabbit 
vaccinated  with HMI:IMSS trophozoites (18), and stored at -20~ 
until use. SCID mice were injected intraperitoneally with 300 #1 
immune rabbit serum or an equivalent  amount ofpreimmune serum 
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amebic  liver  abscess  in  a  SCID 
mouse, 
Figure 2.  Photomicrograph of hematoxylin and eosin-stained section of E.  histolytica liver abscess from SCID mouse.  Amebic trophozoites (arrows) 
can be seen in areas of necrosis within the abscess (A). An intense polymorphonuclear infiltrate is seen in the liver parenchyma (P) adjacent  to necrotic 
areas,  x150. 
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E. histolytica as described above. 
Results and Discussion 
Inbred mouse strains are generally resistant to amebic in- 
fection (19,  20).  In contrast we found that  seven of seven 
SCID mice developed liver abscesses I  wk after inoculation 
of virulent HMI:IMSS E.  histolytica.  Only one of the seven 
congenic immunocompetent C.B-17 mice developed a liver 
abscess (X  2 =  10.5, p <  .001).  The use of virulent hamster 
liver-passaged ameba appears  to be necessary for the estab- 
lishment of amebic liver abscess in SCID mice, since equiva- 
lent quantities of clonally derived HMI:IMSS trophozoites 
which were avirulent in hamster and gerbil liver abscess models 
were incapable of causing abscesses in SCID mice (data not 
shown). 
Abscesses  in SCID mice were grossly visible and usually 
bulging from the liver parenchyma (Fig.  1). Histologic spec- 
imens from SCID liver abscesses revealed eosinophilic areas 
of necrosis with intense, predominantly polymorphonudear 
inflammatory infiltrates in adjacent liver parenchyma (Fig. 
2). Eosinophilic E. histolytica trophozoites could be seen amidst 
the necrotic debris (Fig. 3), and were present throughout the 
abscess cavity, rather than solely at the periphery of the ab- 
scess, as has been described in human liver abscesses (21). The 
intense neutrophilic infiltration seen in hepatic tissue bor- 
dering the SCID mouse liver abscesses is not a regular com- 
ponent of hepatic amebiasis in humans, but it has been reported 
as an early stage of abscess development in animal models 
(22).  The appearance of neutrophils may represent a critical 
role for these cells early in amebic hepatic infection, which 
may be enhanced and longer-lasting in SCID mice because 
of an absence of lymphocyte function. Since our study fo- 
cused on abscesses at a single time point, the natural history 
of abscess formation in SCID mice will require further analysis. 
Whereas SCID mice developed amebic abscesses, equiva- 
lent challenge failed to produce abscesses in all but one of 
the congenic immunocompetent C.B-17 mice. This suggests 
that lymphocyte-based  immunity plays a role in the resistance 
of immunocompetent mice to amebic liver abscess. Addition- 
ally, our data suggests that macrophage, granulocyte, and NK 
cell-mediated resistance is not sufficient to control invasive 
amebic disease in this model, since all of these components 
of inflammatory responses are present in SCID mice. Our 
current model does not speak to the role of these host de- 
fense components in controlling amebic invasion in the in- 
testine, or spread from the intestine to the liver.  In this re- 
Figure 3.  High power detail of hematoxylin-eosin-stained section of amebic liver abscess  in SCID mouse demonstrating multiple  E. histolytica trophozoites 
(arrows) within necrotic  debris,  x 600. 
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intracecal  inoculation of more than  106 virulent HMI:IMSS 
trophozoites failed to establish intestinal infection or disease 
in SCID mice (data not shown). This suggests that the mech- 
anisms that  render  other inbred  mouse strains  resistant  to 
intestinal infection with E. histolytica are intact in SCID mice. 
We subsequently used the SCID mouse model to inves- 
tigate whether passive transfer ofE. histolytica-immune  serum 
would be sufficient to protect against amebic liver abscess. 
We found that a single dose of an E. histolytica-immune  rabbit 
serum administered 24 h before intrahepatic challenge with 
amebic trophozoites provided complete protection from liver 
abscess in 7 of 12 (58%) of SCID mice (Table 1). Preimmune 
antiserum was not protective, as nine of nine control SCID 
mice developed amebic liver abscesses (X  2 =  7.875, p <  .01). 
Antibody has not generally been considered to play an im- 
portant role in resistance to amebiasis (2). Our results, how- 
ever, are consistent with those of Swartzwelder and Avant 
(23), who found in an intestinal model of amebiasis that the 
infection rate of dogs inoculated per anum decreased from 
85 to 30% after passive transfer of immune dog serum.  In 
addition,  Sep61veda et al.  (24) have reported that  hamsters 
passively immunized with E. kistolytica-immune human serum 
that were then challenged intrahepatically with virulent E. 
histolytica developed smaller liver abscesses than unimmunized 
controls. 
The mechanisms by which antibody conferred protection 
remain unclear.  Antibody-dependent ceU-mediated cytotox- 
icity (ADCC) 1 is one possibility.  Neutrophils and eosinophils, 
both of which are intact in the SCID mouse, have been im- 
plicated in the antibody-dependent killing of schistosome para- 
sites  (25,  26).  Provision of E.  histolytica-immune  serum to 
SCID mice may allow ADCC directed against ameba to occur. 
1 Abbreviation used in this  paper." ADCC, antibody-dependent cell-mediated 
cytotoxicity. 
Table  1.  Amebic Liver Abscess  Sizes,  Given as Percent Liver 
Abscessed in SCID Mice Receiving E. histolytica-immune Rabbit 
Serum vs. Preimmune Rabbit Serum 
Immune serum  Preimmune serum 
Mouse  Abscess size  Mouse  Abscess size 
%  % 
1  No abscess  1  10.8 
2  No abscess  2  3.9 
3  13.2  3  1.8 
4  3.8  4  16.6 
5  No abscess  5  7.9 
6  No abscess  6  1.9 
7  No abscess  7  32.6 
8  5.2  8  10.4 
9  5.2  9  8.8 
10  8.7 
11  No abscess 
12  No abscess 
Complement-dependent mechanisms are another possibility. 
Virulent E. histolytica are known to be resistant  to lysis by 
human complement in the absence of detectable antibody (27). 
These virulent  strains may be lysed by mouse complement 
in the presence of anti-E, histolytica rabbit serum (which can 
fix mouse complement). 
We have described a new and potentially valuable model 
for the study of the immunology of amebiasis.  Furthermore, 
a protective role for humoral immunity was found. The es- 
tablishment of a SCID mouse model for amebic liver abscess 
provides a means for further analysis of the contributions of 
humoral and cell-mediated immunity to protection against 
infection with E.  histolytica. 
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